Background:

ATP6AP2, also named as ATP6IP2, CAPER, ELDF10, N14F, ATP6M8-9, Renin receptor and prorenin receptor, is believed to potentiate the renin–angiotensin system(RAS), conferring to prorenin, a likely pathological role at tissue level. The PRR has been identified in the microvascular endothelial cells of the retina, in which it seems to be involved in pathological neovascularization processes. The present study demonstrates for the first time that the PRR is expressed in human ATP6AP2 and suggests a molecular mechanism by which hypertension may exacerbate the pathology of dry AMD.

Clonality:

polyclonal

Classification:

Primary antibody

Alternative names:

APT6M8 9, ATP6AP2, ATP6IP2, ATP6M8 9, CAPER, ELDF10, HT028, M8 9, MRXE, MSTP009, N14F, PRR, PSEC0072, Renin receptor, RENIN RECEPTOR,ATP6AP2, Renin/prorenin receptor, V ATPase M8.9 subunit, XMRE

Specificity:

Human, Mouse, Rat

Host:

Rabbit

Isotype:

IgG

Immunogen:

ATPase, H+ transporting, lysosomal accessory protein 2

Purification:

Immunogen affinity purified

Purity:

≥95% as determined by SDS-PAGE

Calculated molecular weight:

47kd

Form:

liquid

Applications:

ELISA, WB, IHC

Recommended dilution:

WB: 1:500-1:1000; IHC: 1:20-1:200

Storage:

PBS with 0.02% sodium azide and 50% glycerol pH 7.3,-20℃ for 12 months(Avoid repeated freeze / thaw cycles.)

More info:

Email: info@sobekbio.com

Orders:

Email: orders@sobekbio.com